...
首页> 外文期刊>Clinical Epidemiology >A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
【24h】

A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs

机译:关于功效-功效差距的系统文献综述:降糖药物的随机对照试验和观察性研究的比较

获取原文
           

摘要

Aim: To identify a potential efficacy–effectiveness gap and possible explanations (drivers of effectiveness) for differences between results of randomized controlled trials (RCTs) and observational studies investigating glucose-lowering drugs. Methods: A systematic literature review was conducted in English language articles published between 1 January, 2000 and 31 January, 2015 describing either RCTs or observational studies comparing glucagon-like peptide-1 analogs (GLP-1) with insulin or comparing dipeptidyl peptidase-4 inhibitors (DPP-4i) with sulfonylurea, all with change in glycated hemoglobin (HbA1c) as outcome. Medline, Embase, Current Content, and Biosis were searched. Information on effect estimates, baseline characteristics of the study population, publication year, study duration, and number of patients, and for observational studies, characteristics related to confounding adjustment and selection- and information bias were extracted. Results: From 312 hits, 11 RCTs and 7 observational studies comparing GLP-1 with insulin, and from 474 hits, 16 RCTs and 4 observational studies comparing DPP-4i with sulfonylurea were finally included. No differences were observed in baseline characteristics of the study populations (age, sex, body mass index, time since diagnosis of type 2 diabetes mellitus, and HbA1c) or effect sizes across study designs. Mean effect sizes ranged from ?0.43 to 0.91 and from ?0.80 to 1.13 in RCTs and observational studies, respectively, comparing GLP-1 with insulin, and from ?0.13 to 2.70 and ?0.20 to 0.30 in RCTs and observational studies, respectively, comparing DPP-4i and sulfonylurea. Generally, the identified observational studies held potential flaws with regard to confounding adjustment and selection- and information bias. Conclusions: Neither potential drivers of effectiveness nor an efficacy–effectiveness gap were identified. However, the limited number of studies and potential problems with confounding adjustment, selection- and information bias in the observational studies, may have hidden a true efficacy-effectiveness gap.
机译:目的:确定潜在的疗效-疗效差距以及对随机对照试验(RCT)和研究降糖药物的观察性研究之间的差异的可能解释(有效性的驱动因素)。方法:在2000年1月1日至2015年1月31日之间发表的英语文章中进行了系统的文献综述,描述了将胰高血糖素样肽1类似物(GLP-1)与胰岛素或二肽基肽酶4进行比较的RCT或观察性研究磺脲类药物的抑制剂(DPP-4i),所有糖化血红蛋白(HbA1c)的变化均作为结果。搜索Medline,Embase,当前内容和Biosis。有关效果估计值,研究人群的基线特征,发表年份,研究持续时间和患者人数的信息,对于观察性研究,提取与混杂调整,选择和信息偏差有关的特征。结果:从312个结果中,包括GLP-1和胰岛素的11个RCT和7个观察性研究,以及从DPP-4i和磺酰脲类中比较的474个结果的16个RCT和4个观察性研究。在整个研究设计中,研究人群的基线特征(年龄,性别,体重指数,自诊断为2型糖尿病以来的时间和HbA1c)未观察到差异或效应量没有差异。比较GLP-1和胰岛素,RCT和观察性研究的平均效应大小分别为0.43至0.91和0.80至1.13,RCT和观察性研究的平均效应大小分别为0.13至2.70和0.20至0.30。 DPP-4i和磺酰脲类。一般而言,已确定的观察性研究在调整,选择和信息偏差方面存在潜在的缺陷。结论:既未发现有效性的潜在驱动因素,也未发现功效-功效差距。然而,观察研究中有限的研究数量和潜在的问题,包括调整,选择和信息偏差等混杂因素,可能掩盖了真正的功效差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号